Quetiapine is a dibenzothiazepine derivative, structurally related to cloazapine which has been used clinically since 1997 as a neuroleptic agent in the treatment of psychosis. Daily doses may range from 150 - 800 mg and are usually administered in 2 - 3 portions.
Adverse reactions to quetiapine therapy include somnolence, hypertension, dizziness, dry mouth and dyspepsia. Neuroleptic malignant syndrome has also been reported.
For TDM, sample should be taken prior to dose. If toxicity is suspected, take sample at earliest opportunity
Quetiapine measured by LC-MS/MS.
Therapeutic range: 100 - 500 μg/L. Toxicity associated with concentrations >1000 μg/L. (Schulz et al. Critical Care 2012, 16:R136).
Copyright heftpathology 2013, 2014, 2015, 2016, 2017, 2018
HTA licence number is 12366
Protection of Personal Information – Laboratory Medicine comply with the Trust Data Protection Policy and have procedures in place to allow the Directorate and it’s employees to comply with the Data Protection Act 1998 and associated best practice and guidance.
The Trust Laboratories at Heartlands Hospital, Good Hope Hospital and Solihull Hospital were awarded UKAS (United Kingdom Accreditation Service) accreditation to the internationally recognised ISO 15189 standard in May 2015. For a list of accredited tests and other information please visit the test database http://www.heftpathology.com/frontpage/test-database.html.
Tests not appearing on this scope are either under consideration or in the process of accreditation and so currently remain outside of our scope of accreditation. However, these tests have been validated to the same high standard as accredited tests and are performed by the same trained and competent staff.
For further information contact Louise Fallon, Quality Manager, 0121 424 1235